<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03639766</url>
  </required_header>
  <id_info>
    <org_study_id>BIO-18-14092</org_study_id>
    <nct_id>NCT03639766</nct_id>
  </id_info>
  <brief_title>The Effect of Abobotulinum Toxin A on the Symptoms of Raynaud's Phenomenon</brief_title>
  <official_title>The Effect of Abobotulinum Toxin A on the Symptoms of Raynaud's Phenomenon, a Double-Blind Randomized Placebo-Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Central Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Central Florida</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate the effect of abobotulinum toxin A on the symptoms of
      Raynaud's phenomenon.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective double-blind randomized control trial seeks to compare a single formulation
      of BoNT, aboboutlinum toxin A (Dysport), to a placebo saline group, studying the effect of
      BoNT on Raynaud's symptoms among a more diverse population to provide insight into the
      patients most likely to benefit from BoNT.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Time and resource constraints
  </why_stopped>
  <start_date type="Actual">August 31, 2018</start_date>
  <completion_date type="Actual">January 31, 2020</completion_date>
  <primary_completion_date type="Actual">January 31, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a two-arm parallel assignment involves two groups of participants. One group/hand receives the abobotulinum toxin A, and the other group/hand receives a saline solution (control).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>This is a double-blind placebo-controlled trial.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Raynaud's Condition Score</measure>
    <time_frame>12 months</time_frame>
    <description>Raynaud's Condition Score is a validated outcome measure used to assess a person's functionality owing to their Raynaud's symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>QuickDASH</measure>
    <time_frame>12 months</time_frame>
    <description>QuickDASH is a validated outcome measure used to assess symptoms and functionality based on a person's Raynaud's symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>VAS for Pain</measure>
    <time_frame>12 months</time_frame>
    <description>The VAS for Pain is a validated scale used to assess patient's pain on a scale of 1-10.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Raynaud Phenomenon</condition>
  <arm_group>
    <arm_group_label>Abobotulinum toxin A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection of 300 units of abobotulinum toxin A in 10 ml of non-bacteriostatic normal saline to chosen hand.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Injection of 10 ml of non-bacteriostatic normal saline to chosen hand.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AbobotulinumtoxinA</intervention_name>
    <description>AbobotulinumtoxinA reconstituted in non-bacteriostatic saline solution</description>
    <arm_group_label>Abobotulinum toxin A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline solution</intervention_name>
    <description>Non-bacteriostatic saline solution</description>
    <arm_group_label>Saline solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female adult between 18 and 80 years of age

          -  Must have health insurance

          -  Must have a current diagnosis of Raynaud's phenomenon

        Exclusion Criteria:

          -  Allergy to abobotulinum toxin A or its components

          -  Diagnosis of myasthenia gravis

          -  Previously received abobotulinum toxin vaccine

          -  Previously undergone upper extremity vascular surgery (including surgical
             sympathectomy)

          -  Currently receiving aminoglycoside antibiotics

          -  Received abobotulinum toxin A treatment in either hand in the past 6 months

          -  Pregnant women

          -  Women currently breastfeeding

          -  Current tobacco smoker (use in the past 12 months)

          -  Unable to read and speak English

          -  Adults unable to consent

          -  Individuals who are not yet adults (infants, children, teenagers)

          -  Prisoners
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UCF Health Lake Nona Office</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32827</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 17, 2018</study_first_submitted>
  <study_first_submitted_qc>August 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2018</study_first_posted>
  <last_update_submitted>March 23, 2020</last_update_submitted>
  <last_update_submitted_qc>March 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Central Florida</investigator_affiliation>
    <investigator_full_name>David Weinstein</investigator_full_name>
    <investigator_title>Assistant Professor of Dermatology</investigator_title>
  </responsible_party>
  <keyword>Raynaud Phenomenon</keyword>
  <keyword>AbobotulinumtoxinA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raynaud Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>abobotulinumtoxinA</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

